Recent advances in sepsis research

Novel biomarkers and therapeutic targets

B. Ivády, B. J. Béres, D. Szabó

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Sepsis remains a common cause of death in the intensive care units worldwide. However, in the last decade a significant development could be noticed in sepsis research regarding diagnostic markers that can help the physicians to recognize the disease in the early phase, which is the clue of the successful treatment of sepsis. This development provided the identification of new molecules and structures (i.e. cytokins, cell surface markers, receptors) that are potential biomarkers of sepsis in the clinical settings. Besides, the advance in the understanding of the pathophysiologic, immunologic and biochemical pathway of sepsis has made the way for assignment of new drug targets in the therapy of sepsis. This review aims to provide a summary about these novelties regarding our knowledge about sepsis published in the medical literature recently. We will describe the presumed pathophysiological role and diagnostic value of sepsis markers that are used even more widely in the clinical practice (i.e. procalcitonin, IL-6), summarize the data regarding the sepsis marker candidates that are investigated in some initial study (i.e. matrix metalloproteinases, microRNA fingerprints), and we will discuss substances that may be specific markers for certain organ failures related to sepsis (i.e. neutrophil gelatinase-derived lipocalin in acute renal failure). Furthermore, we will review the mediators of the immuno-inflammatory cascade in sepsis concerning their potential applicability as therapeutic targets in the treatment of this often lethal disease. In addition, we present some insights into the identification of genetic markers of sepsis.

Original languageEnglish
Pages (from-to)3211-3225
Number of pages15
JournalCurrent Medicinal Chemistry
Volume18
Issue number21
DOIs
Publication statusPublished - Jul 2011

Fingerprint

Biomarkers
Sepsis
Lipocalins
Intensive care units
Gelatinases
Calcitonin
Matrix Metalloproteinases
MicroRNAs
Research
Interleukin-6
Molecules
Therapeutics
Pharmaceutical Preparations
Dermatoglyphics
Cell Surface Receptors
Genetic Markers
Acute Kidney Injury
Intensive Care Units
Cause of Death
Neutrophils

Keywords

  • Brain type natriuretic peptide
  • Diagnosis
  • Interleukin-6
  • Marker
  • Matrix metalloproteinase
  • Neutrophil gelatinase-associated lipocalin
  • Organ failure
  • Procalcitonin
  • Prognosis
  • Sepsis
  • Septic shock
  • Therapeutic target
  • Therapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Recent advances in sepsis research : Novel biomarkers and therapeutic targets. / Ivády, B.; Béres, B. J.; Szabó, D.

In: Current Medicinal Chemistry, Vol. 18, No. 21, 07.2011, p. 3211-3225.

Research output: Contribution to journalArticle

@article{9c4e4456c7084e87857845f62308f216,
title = "Recent advances in sepsis research: Novel biomarkers and therapeutic targets",
abstract = "Sepsis remains a common cause of death in the intensive care units worldwide. However, in the last decade a significant development could be noticed in sepsis research regarding diagnostic markers that can help the physicians to recognize the disease in the early phase, which is the clue of the successful treatment of sepsis. This development provided the identification of new molecules and structures (i.e. cytokins, cell surface markers, receptors) that are potential biomarkers of sepsis in the clinical settings. Besides, the advance in the understanding of the pathophysiologic, immunologic and biochemical pathway of sepsis has made the way for assignment of new drug targets in the therapy of sepsis. This review aims to provide a summary about these novelties regarding our knowledge about sepsis published in the medical literature recently. We will describe the presumed pathophysiological role and diagnostic value of sepsis markers that are used even more widely in the clinical practice (i.e. procalcitonin, IL-6), summarize the data regarding the sepsis marker candidates that are investigated in some initial study (i.e. matrix metalloproteinases, microRNA fingerprints), and we will discuss substances that may be specific markers for certain organ failures related to sepsis (i.e. neutrophil gelatinase-derived lipocalin in acute renal failure). Furthermore, we will review the mediators of the immuno-inflammatory cascade in sepsis concerning their potential applicability as therapeutic targets in the treatment of this often lethal disease. In addition, we present some insights into the identification of genetic markers of sepsis.",
keywords = "Brain type natriuretic peptide, Diagnosis, Interleukin-6, Marker, Matrix metalloproteinase, Neutrophil gelatinase-associated lipocalin, Organ failure, Procalcitonin, Prognosis, Sepsis, Septic shock, Therapeutic target, Therapy",
author = "B. Iv{\'a}dy and B{\'e}res, {B. J.} and D. Szab{\'o}",
year = "2011",
month = "7",
doi = "10.2174/092986711796391598",
language = "English",
volume = "18",
pages = "3211--3225",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "21",

}

TY - JOUR

T1 - Recent advances in sepsis research

T2 - Novel biomarkers and therapeutic targets

AU - Ivády, B.

AU - Béres, B. J.

AU - Szabó, D.

PY - 2011/7

Y1 - 2011/7

N2 - Sepsis remains a common cause of death in the intensive care units worldwide. However, in the last decade a significant development could be noticed in sepsis research regarding diagnostic markers that can help the physicians to recognize the disease in the early phase, which is the clue of the successful treatment of sepsis. This development provided the identification of new molecules and structures (i.e. cytokins, cell surface markers, receptors) that are potential biomarkers of sepsis in the clinical settings. Besides, the advance in the understanding of the pathophysiologic, immunologic and biochemical pathway of sepsis has made the way for assignment of new drug targets in the therapy of sepsis. This review aims to provide a summary about these novelties regarding our knowledge about sepsis published in the medical literature recently. We will describe the presumed pathophysiological role and diagnostic value of sepsis markers that are used even more widely in the clinical practice (i.e. procalcitonin, IL-6), summarize the data regarding the sepsis marker candidates that are investigated in some initial study (i.e. matrix metalloproteinases, microRNA fingerprints), and we will discuss substances that may be specific markers for certain organ failures related to sepsis (i.e. neutrophil gelatinase-derived lipocalin in acute renal failure). Furthermore, we will review the mediators of the immuno-inflammatory cascade in sepsis concerning their potential applicability as therapeutic targets in the treatment of this often lethal disease. In addition, we present some insights into the identification of genetic markers of sepsis.

AB - Sepsis remains a common cause of death in the intensive care units worldwide. However, in the last decade a significant development could be noticed in sepsis research regarding diagnostic markers that can help the physicians to recognize the disease in the early phase, which is the clue of the successful treatment of sepsis. This development provided the identification of new molecules and structures (i.e. cytokins, cell surface markers, receptors) that are potential biomarkers of sepsis in the clinical settings. Besides, the advance in the understanding of the pathophysiologic, immunologic and biochemical pathway of sepsis has made the way for assignment of new drug targets in the therapy of sepsis. This review aims to provide a summary about these novelties regarding our knowledge about sepsis published in the medical literature recently. We will describe the presumed pathophysiological role and diagnostic value of sepsis markers that are used even more widely in the clinical practice (i.e. procalcitonin, IL-6), summarize the data regarding the sepsis marker candidates that are investigated in some initial study (i.e. matrix metalloproteinases, microRNA fingerprints), and we will discuss substances that may be specific markers for certain organ failures related to sepsis (i.e. neutrophil gelatinase-derived lipocalin in acute renal failure). Furthermore, we will review the mediators of the immuno-inflammatory cascade in sepsis concerning their potential applicability as therapeutic targets in the treatment of this often lethal disease. In addition, we present some insights into the identification of genetic markers of sepsis.

KW - Brain type natriuretic peptide

KW - Diagnosis

KW - Interleukin-6

KW - Marker

KW - Matrix metalloproteinase

KW - Neutrophil gelatinase-associated lipocalin

KW - Organ failure

KW - Procalcitonin

KW - Prognosis

KW - Sepsis

KW - Septic shock

KW - Therapeutic target

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=79959939222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959939222&partnerID=8YFLogxK

U2 - 10.2174/092986711796391598

DO - 10.2174/092986711796391598

M3 - Article

VL - 18

SP - 3211

EP - 3225

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 21

ER -